Angiographic and clinical outcome following paclitaxel-eluting stent (Taxus) implantation

International Heart Journal

Volumn 47, Issue 1, 2006, Pages 1-12

  Doven, Oben ^a   Özcan, Turkay I ^a   Cicek, Dilek ^a   Camsari, Ahmet ^a   Akkus, Necdet ^a   Aytacoglu, Barlas N ^a   Ozeren, Murat ^a   Camdeviren, Handan ^a   Cin, Veli Gokhan ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Angioplasty; Drug eluting stents; In stent restenosis; Paclitaxel; Taxus

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORASPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOMEPROL; IOMERON 400; IOPROMIDE; LIQUEMINE FLACON; PACLITAXEL; POLYMER; TIROFIBAN; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; CLINICAL TRIAL; MIDDLE AGED; RADIOGRAPHY; RESTENOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 33344470738     PISSN: 13492365     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.47.1     Document Type: Article

References (32)

1. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994; 330: 981-93. (Review)
2. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39:183-93. (Review)
3. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247-54.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-14.
5. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six and twelve month results from and randomized, double-blind trial on a slow release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
6. Peterson ED, Lansky AJ, Anstrom KJ, et al. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. Am Heart J 2000; 139: 198-207.
7. Edelman ER, Rogers C. Hoop dreams. Stents without restmosis. Circulation 1996; 94: 1199-202.
8. Mchta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 2001; 358: 527-33.
9. Herdeg C, Oberhoff M, Baumbach A, et al Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35: 1969-76.
10. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95.
11. Rankin JM, Spinelli JJ, Carere RG. et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med 1999; 341: 1957-65.
12. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555-62. (Review)
13. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994; 89: 2816-21.
14. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995; 25: 516-20. (Review)
15. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-27.
16. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7.
17. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45.
18. Grube E, Silber S, Hauptrmann KE, et al. Taxus I: Six and twelve-month results from a rardomized doubleblind trial on a slow-release poclitaxel-eluting stent for de nors coronory lesions. Circulation 2003; 107: 38-42.
19. Tanabe K, Serruys PW, Degeriekin M, et al. TAXUS II Study Group. Incomplete stent apposition after implantation of pachtaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation. 2005; 111: 900-5.
20. Tanabe K, Serruys PW, Grube E, el al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-64.
21. Stone GW, Ellis SG, Cox DA, et al. TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-7.
22. Halkin A, Stone GW. Polymer-based pachtaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 2004; 17: 271-82. (Review)
23. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important still much to learn. J Am Coll Cardiol 2004; 44: 1373-85. (Review)
24. Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description echanistic analysis from a consecutive series ofcases. Circulation 2003; 108: 257-60.
25. Moreno R, Fernandes C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-9.
26. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-5.
27. Colombo A, Drzewiecki J, Banning A, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-94.
28. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997; 95: 1366-9.
29. Hamiller JB, Raizner A, Cannon L, et al. TAXUS-IV Investigators. Outcomes with the polymer-based pacli-taxel-eluting TAXUS stent in patients with diabetes mellitus: the Taxus-IV trial. J Am Coll Cardiol 2005; 45: 1172-9.
30. Sdringola S, Assali AR, Ghani M, et al. Risk assesment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc, Interv 2001; 54: 318-24.
31. Savage MP, Douglas JS Jr, Fischman DL, et al. Saphenous Vein De Novo Trial Investigators. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Eng J Med 1997; 337: 740-7.
32. Cicek D, Doven O, Pekdemir H, et al. Procedural results and distal embolization after saphenous vein graft stenting and angioplasty for in-stent restenosis of grafts. Jpn Heart J 2004; 45: 561-71.